Cancer research identifies new molecular targets for tumor growth and resistance

Researchers have identified new molecular mechanisms and potential therapeutic targets in cancer progression. At the University of New Mexico, studies indicate that PINK1 deficiency facilitates mitochondrial iron accumulation, which contributes to colon tumorigenesis. While PINK1 ablation activates the NLRP3 inflammasome and releases IL1B, inhibiting this specific signaling pathway did not prevent colon tumor growth in models, suggesting the need for different druggable targets related to iron ion transmembrane transporter activity.

In a separate study involving the University of Kentucky and the Broad Institute, scientists identified S6K1 (RPS6KB1) as a critical vulnerability in tumors that exhibit plasticity and resistance to therapy. Using a chemical biology approach and a drug library screen, researchers developed a derivative of the antihistamine ebastine, termed ‘Super-ebastine’ (Super-EBS), which targets these resistant cancer cells.